X4 Pharmaceuticals Inc. Company Profile
NASDAQ: XFORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 2.81 +0.72%
X4 Pharmaceuticals at a glance
X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. X4 Pharmaceuticals employs about 45 people. The company's shares have traded publicly since 2017.
At a market capitalization of $278.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001501697, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- X4 Pharmaceuticals Inc.
- Ticker
- NASDAQ: XFOR
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 45
- Headquarters
- 61 North Beacon Street, Boston, MA, United States
- Phone
- 857 529 8300
- Website
- x4pharma.com
- IPO year
- 2017
- Market cap
- $278.60M
- SEC CIK
- 0001501697
- Latest annual report
- 10-K · Mar 17, 2026
Companies similar to X4 Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IKTInhibikase Therapeutics Inc. | 1.91 | -1.55% | $266.51M | vs XFOR |
| IPSCCentury Therapeutics Inc. | 1.46 | +14.06% | $264.37M | vs XFOR |
| LXEOLexeo Therapeutics Inc. | 3.21 | -3.02% | $263.50M | vs XFOR |
| SABSSAB Biotherapeutics Inc. | 2.89 | +0.35% | $262.95M | vs XFOR |
| LCTXLineage Cell Therapeutics Inc. | 1.03 | +8.70% | $260.49M | vs XFOR |
| FATEFate Therapeutics Inc. | 2.13 | -0.93% | $255.22M | vs XFOR |
| STROSutro Biopharma Inc. | 15.32 | +4.50% | $254.02M | vs XFOR |
| PALIPalisade Bio Inc. | 1.45 | -2.03% | $252.69M | vs XFOR |